University of Salamanca

GSK's Blenrep showed a 42% reduced risk of death in multiple myeloma, outperforming Darzalex in the DREAMM-7 trial. With a 74% OS rate for BVd vs. 60% for DVd, and significant MRD negativity, it may redefine treatment for relapsed/refractory multiple myeloma. GSK aims for Blenrep's comeback, despite competition from newer therapies.

DREAMM-7 trial results show belantamab mafodotin combination significantly improves overall survival in relapsed/refractory multiple myeloma patients compared to daratumumab combination, with a 42% risk reduction in death. The combination also shows superior minimal residual disease negativity and other key efficacy endpoints, supporting its potential as a new standard of care.

Belantamab mafodotin combination (BVd) showed significant OS improvement and MRD negativity over daratumumab combination (DVd) in relapsed/refractory multiple myeloma patients, indicating deeper, durable responses. Safety profiles were consistent with known risks, with manageable eye-related side effects. Regulatory filings for BVd in multiple regions are underway.

The phase III DREAMM-7 study showed belantamab mafodotin-blmf combined with bortezomib and dexamethasone (BVd) significantly improved progression-free survival in relapsed/refractory multiple myeloma, with a median of 36.6 months vs 13.4 months for DVd. BVd also showed a trend towards better overall survival and higher response rates, despite more serious adverse events, including ocular effects.

HER2-positive breast cancer benefits from targeted therapies like trastuzumab, but resistance remains a challenge. Antibody-drug conjugates (ADCs), combining cytotoxic agents with antibodies targeting HER2, offer a promising solution. Two ADCs, trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-DXd), are FDA-approved, with others in development. These ADCs aim to overcome resistance through innovative structures, mechanisms of action, and strategies to bypass resistance mechanisms, enhancing treatment efficacy for HER2-positive cancers.